# FDA 483 - Hanlim Pharm Co., Ltd. - February 06, 2018

Source: https://www.keypedia.com/records/483/hanlim-pharm-co-ltd/22b865c6-cf21-4758-84f3-182b1bbd11c9

> FDA 483 for Hanlim Pharm Co., Ltd. on February 06, 2018. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Hanlim Pharm Co., Ltd.
- Inspection Date: 2018-02-06
- Product Type: drugs
- Office Name: International Compliance Team
- Summary: An FDA inspection of HanLim Pharm Co., Ltd. in Yonginsi Ceoin-gu, Korea, a sterile OTC drug manufacturer, revealed multiple significant deficiencies. These included failures in aseptic processing procedures, inadequate validation of sterilization processes, and insufficient laboratory controls for product specifications. The firm also exhibited issues with data integrity, personnel training for critical operations, and environmental monitoring in aseptic areas, indicating a broad lack of control over manufacturing processes designed to ensure product sterility and quality.

## Related Documents

- [483 - 2022-05-31](https://www.keypedia.com/records/483/hanlim-pharm-co-ltd/c5475f6a-9ba6-4b4c-9b8c-bfca3bd1130b)

## Related Officers

- [Senior Advisor](https://www.keypedia.com/people/rachel-c-harrington/254a4217-8cd8-4a79-bf24-9345d34d0550)

Company: https://www.keypedia.com/companies/hanlim-pharm-co-ltd/2d7a6160-8193-4d7a-b9bd-569bfcbf933f

Office: https://www.keypedia.com/offices/international-compliance-team/f0ce0d89-bf39-46c6-8c42-28138d161321